BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2020

View Archived Issues

AbbVie conducts phase Ib study of eftozanermin alfa in relapsed or refractory multiple myeloma

Read More

Enrollment ongoing in phase II study of HTD-1801 in primary biliary cholangitis

Read More

Novel potent PI3Kdelta inhibitors that target two different mechanisms of isoform selectivity

Read More

AK-002 reduces GI eosinophils and symptoms in eosinophilic gastritis/duodenitis: phase I results

Read More

Regenerative approach shows promise in pediatric heart disease

Read More

hAd5-COVID-19 vaccine candidate protects nasal and lung airways in nonhuman primates

Read More

Preliminary clinical data for proxalutamide in COVID-19

Read More

ProTrans-Repeat meets its primary safety endpoint at 24 months

Read More

Leqvio approved in Europe for the treatment of hypercholesterolemia or mixed dyslipidemia

Read More

Tychan to initiate phase III study of TY-027 in patients with COVID-19

Read More

PureTech initiates phase I study of LYT-200 in metastatic solid tumors

Read More

Phase I data presented for CTA-101 in patients with R/R B-cell ALL

Read More

TAK-573 shows clinical activity in relapsed/refractory multiple myeloma in first-in-human study

Read More

Exploratory study suggests ZYN-002 reduces seizures in children with encephalopathies

Read More

Hinova Pharmaceuticals patents new PROTACs

Read More

Cadila Healthcare discloses new compounds for tuberculosis

Read More

Italian researchers identify new compounds for HBV infection

Read More

Boryung Pharmaceutical describes new PI3Kdelta and/or DNA-PK inhibitors

Read More

Suzhou Ribo Life Science patents FXI-targeting siRNA

Read More

MET no better than EMT for cancer metastases

Read More

Amarin reports data on Vascepa in COVID-19 outpatients

Read More

Aerpio announces phase II data on razuprotafib in glaucoma

Read More

Akari releases long-term data on nomacopan in paroxysmal nocturnal hemoglobinuria

Read More

Ultimovacs reports 5-year survival data from phase I trial of UV-1 in metastatic melanoma

Read More

Phase III study of ruxolitinib in COVID-19 does not meet primary endpoint

Read More

PMD-026 shows safety and initial signs of activity in metastatic breast cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing